TABLE 2.
Summary of patients' demographics
| Variable | Count (% of total)/median (interquartile range) | |
|---|---|---|
| Age | 54 (36–72) years | |
| Gender | Female | 46 (59.7%) |
| Male | 29 (37.7%) | |
| Not mentioned | 2 (2.6%) | |
| Vaccine type | Ad26.COV2.S | 2 (2.6%) |
| BNT16B2b2 mRNA | 35 (45.5%) | |
| ChAdOx1. | 17 (22.1%) | |
| mRNA‐1273 | 23 (29.9%) | |
| Vaccine dose | First | 61 (79.2%) |
| Second | 14 (18.2%) | |
| Third/booster dose | 1 (1.3%) | |
| Not mentioned | 1 (1.3%) | |
| Positive history of autoimmune disease | 8 (10.4%) | |
| ITP disease presentation | Skin manifestation | 8 (10.4%) |
| Mucosal manifestation | 32 (41.6%) | |
| Internal organs manifestation | 17 (22.1%) | |
| Onset of ITP symptoms from vaccination day | 7 (3–12) days | |
| Platelets prior to vaccination | 220 (172.5–255) × 109/L | |
| Platelets on admission | 3 (2–10) × 109/L | |
| Platelets' nadir | 4.5 (1.25–26.75) × 109/L | |
| ITP related antibodies | Negative anti‐platelet factor 4 | 16 (20.8%) |
| Positive anti‐platelet factor 4 | 0 (0%) | |
| Positive anti‐glycoprotein IIb/IIIa | 16 (20.8%) | |
| Negative anti‐glycoprotein IIb/IIIa | 16 (20.8%) | |
| Positive non‐specific antibodies against platelets | 4 (5.1%) | |
| Management settings of patients | Outpatients | 2 (2.5%) |
| Inpatients | 67 (87%) | |
| Not Mentioned | 8 (10.5%) | |
| Hospital stay of admitted patients | 6 (4–13) days | |
| Treatment | Glucocorticoids in total | 62 (80.5%) |
| Prednisolone or methylprednisolone | 34 (44.2%) | |
| Dexamethasone | 19 (24.7%) | |
| Intravenous immunoglobulin | 47 (61%) | |
| Thrombopoietin receptor agonists in total | 12 (15.6%) | |
| Eltrombopag | 8 (10.4%) | |
| Romiplostim | 3 (3.9%) | |
| Platelet transfusion | 30 (39.0%) | |
| Follow‐up platelets | 140 (71–248) × 109/L | |